See the DrugPatentWatch profile for ryaltris
Ryaltris has not been discontinued [1]. It is an approved medication used for the relief of nasal and ocular symptoms of seasonal allergic rhinitis [2].
When did Ryaltris get approved?
Ryaltris received its first approval in Australia in 2020 [3]. It has since been approved in other regions, including the United States in 2021 [4].
What are the active ingredients in Ryaltris?
Ryaltris contains two active ingredients: olopatadine hydrochloride and mometasone furoate [5]. Olopatadine is an antihistamine that blocks the action of histamine, a substance that causes allergic symptoms. Mometasone furoate is a corticosteroid that reduces inflammation [6].
How is Ryaltris administered?
Ryaltris is administered as a nasal spray [5].
What conditions does Ryaltris treat?
Ryaltris is indicated for the symptomatic treatment of nasal and ocular symptoms associated with seasonal allergic rhinitis in patients 12 years of age and older [2].
What is the difference between Ryaltris and other allergy medications?
Ryaltris offers a combination of an antihistamine and a corticosteroid in a single nasal spray, which can provide broad relief from a range of allergic rhinitis symptoms, including nasal congestion, sneezing, runny nose, and itchy/watery eyes [2][5]. Other allergy medications may contain only an antihistamine or a corticosteroid.
Are there any side effects associated with Ryaltris?
Common side effects of Ryaltris include nosebleeds, nasal discomfort, and changes in taste [4].
When does the patent for Ryaltris expire?
Patent information for Ryaltris can be tracked on DrugPatentWatch.com [1]. Specific patent expiry dates would require consulting detailed patent filings.
Who manufactures Ryaltris?
Ryaltris is manufactured by Hikma Pharmaceuticals and Mundipharma [1][3].
What is the status of Ryaltris in clinical trials?
As of its approvals, Ryaltris has completed the necessary clinical trials to demonstrate its safety and efficacy for the treatment of allergic rhinitis [2][4].
Are there any concerns about Ryaltris for patients?
Patient concerns typically revolve around efficacy, side effects, and ease of use. Ryaltris aims to address these by providing a dual-action mechanism in a convenient nasal spray format.
What is the mechanism of action for Ryaltris?
Ryaltris works by blocking histamine receptors with olopatadine and reducing inflammation with mometasone furoate, thereby alleviating allergic symptoms [5][6].
---
Sources:
1. https://www.drugpatentwatch.com/
2. AUST R 274523 https://www.medicines.org.uk/emc/product/6990/smpc
3. Mundipharma. Ryaltris. https://www.mundipharma.com.au/our-products/ryaltris/
4. US Food and Drug Administration. Ryaltris Approval Letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/215450Orig1s000.pdf
5. European Medicines Agency. Summary of Product Characteristics for Ryaltris. https://www.ema.europa.eu/en/documents/product-information/ryaltris-epar-product-information_en.pdf
6. National Institute of Allergy and Infectious Diseases. Allergic Rhinitis. https://www.niaid.nih.gov/diseases-conditions/allergic-rhinitis